VCEL (Vericel) Risk Assessment


VCEL Vericel Corp VCEL
81 GF Score
Price $46.98
GF Value $54.64
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Vericel Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Vericel is: Moderate Risk: Sensitive, better choose undervalued stock.

Vericel  (NAS:VCEL) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Vericel Risk Assessment Related Terms

VCEL vs NRIX, MLYS, PHVS: Risk Assessment Comparison

For the Biotechnology subindustry, Vericel's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vericel Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vericel's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Vericel's Risk Assessment falls into.


VCEL
81GF Score
Vericel Corp VCEL
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vericel (VCEL) Overvalued in 2026?

Based on GuruFocus' analysis, Vericel stock appears to be undervalued. The current stock price of $46.98 is trading 14% below its estimated GF Value™ of $54.64. GuruFocus considers Vericel to be Modestly Undervalued.

Key valuation signals for VCEL:

  • Risk Assessment:
  • GF Value™: $54.64 vs. price of $46.98 (14% below fair value)
  • GF Score™: 81/100 with 7 warning signs

No single metric tells the full story. See the VCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vericel Business Description

Other Exchanges ATQP:Germany
Address 64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
81GF Score

Get the complete analysis for VCEL

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.98
Price
$54.64
GF Value